DAWN

Day One Biopharmaceuticals Stock Analysis

AI Rating

Fair
  • Quality2/10
  • Growth↑ 6/10
  • Value↓ 0/10
Day One Biopharmaceuticals sales and earnings growth
DAWN Growth
Good
  • Revenue Y/Y↑ 20.60%
  • EPS Y/Y↓ -1.96%
  • FCF Y/Y↓ -475.37%
Day One Biopharmaceuticals gross and profit margin trends
DAWN Profitability
Neutral
  • Gross margin ↑ 89.10%
  • EPS margin↓ -67.80%
  • ROIC 5Y↓ -80.49%
Day One Biopharmaceuticals net debt vs free cash flow
DAWN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Day One Biopharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗